Global TRK Inhibitors Market, Drug Sales & Clinical Trials insight 2026

October 2021 | 180 pages | ID: GA70D7B4D7FBEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:

• Research Methodology
• Global & Regional Market Analysis
• Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
• Market & Drug Sales Insight 2020 Till 2026
• Approved Drug In Market: 2 Drugs
• Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
• Future Market Assessment By Indication Till 2026
• Ongoing Clinical Trials Assessment by Status, Phase & Region
• Key Market Dynamics
• Competitor Landscape

The advancement in the field of biotechnology has promoted the recognition of the presence of targetable genomic alterations across multiple tumor types. Lately, researchers have identified NTRK gene fusions involving NTRK1, NTRK2, or NTRK3 encoding the neurotropin receptors TRKA, TRKB, and TRKC respectively as the oncogenic driver in several adult and pediatric cancers. Their critical role in the development, progression, and metastasis of cancer has made it potential target as an alternative for the treatment for the cancer. Since then, researchers have indulged in several research and development activities for the development of effective TRK inhibitors.

Currently, two TRK inhibitors including Vitrakvi and Rozlytrek have gained approval bodies for the management of NTRK positive solid tumors. The commercial launch of these drugs in the market has shown to completely transform the paradigm treatment of NTRK positive cancer. Since their introduction into the market, these drugs have shown high adoption rates which is mainly attributed to their high specificity and selectivity to NTRK genes, and its ability to overcome the limitation of conventional cancer therapies. Apart from this, these drugs have shown to cross the blood brain barrier, thus indicating its potential role in brain tumors.

In addition to approved drugs, the global pipeline of TRK inhibitors is highly crowded which suggests a brighter future of these inhibitors. The other TRK inhibitors in the pipeline are mainly developed to overcome the resistance to first generation TRK inhibitors. Selitrectinib (LOXO-195) and Repotrectinib (TPX-005) are the two next generation TRK inhibitors which have efficacy against TRK with acquired resistance. Currently, these are present in phase-II clinical trial and are expected to enter the market during the forthcoming years. Furthermore, several other potential candidates including Taletrectinib, VMD928, ICP723, and CHC2014 are also present in early phase of clinical trials and have shown promising preclinical activities.

The overall TRK inhibitor market is highly competitive and the key players working in market are AstraZeneca, Pfizer, Bayer, Loxo Oncology, Innocare, Ono Pharmaceutical, and Turning Point Therapeutics. The pharmaceutical giants have adopted several strategies to remain at forefront including agreement, mergers, joint ventures, collaboration, or acquisitions. For instance in May, 2021 AUM Biosciences entered into collaboration agreement with Handok and CMG Pharmaceutical for the worldwide development, manufacturing, and commercialization rights of CHC2014 which is highly specific and efficacious pan-TRK inhibitor.

Currently, the global TRK inhibitor market is present at nascent stage owing to the approval of two drugs. However, it is expected that the coming years will witness tremendous growth rates in the market which is mainly due to increase in prevalence of cancer and the unmet need for the targeted therapy. Apart from this, the increase in awareness about the availability of drugs, upcoming new drugs approval, and rise in government initiatives will also boost the growth of market.

United States is anticipated to have a dominant share in the market during the forecast period, due to rise in awareness about new drugs for treatment, availability of all major companies in the region, the introduction of new drugs, and high prevalence of cancer in the region. Apart from this, the presence of favorable reimbursement policies including Vitrakvi Co-Pay by Bayer or Rozlytrek Co-Pay by Genentech to reduce the out of pocket cost associated with drugs will also increase the adoption rates of TRK inhibitor drugs in the region.

The report provides insights into the patent, price, dosage and sales analysis of the currently approved TRK inhibitors. On the basis of indication, the market is segment into lung, colorectal, breast, glioblastoma and papillary thyroid cancer. Keeping in mind the various driver and challenges, the future outlook of TRK inhibitors has also been analyzed in the report.

Contents

1. INTRODUCTION TO TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS

1.1 Overview to TRK Inhibitors
1.2 Evolution of TRK Inhibitors

2. TRK - POTENTIAL TARGET IN CANCER THERAPY

3. TRK INHIBITORS MECHANISM OF ACTION

4. GLOBAL TRK INHIBITOR MARKET INSIGHT

4.1 Market Overview
4.2 Current Market Trends

5. TRK INHIBITORS MARKET REGIONAL ANALYSIS

5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World

6. TRK INHIBITORS MARKET BY INDICATION

6.1 Lung Cancer
6.2 Breast Cancer
6.3 Colorectal Cancer
6.4 Papillary Thyroid Cancer
6.5 Glioblastoma

7. VITRAKVI (LAROTRECTINIB) – FIRST APPROVED TRK INHIBITOR

7.1 Overview
7.2 Patents & Assignees

8. VITRAKVI (LAROTRECTINIB) – COMMERCIAL INFORMATION

8.1 Pricing
8.2 Sales Analysis

9. ROZLYTREK (ENTRECTINIB) – SECOND APPROVED TRK INHIBITOR

9.1 Overview
9.2 Patents & Assignees

10. ROZLYTREK (ENTRECTINIB) – COMMERCIAL INFORMATION

10.1 Price & Dosage Anlaysis
10.2 Sales Analysis

11. TRK INHIBITORS SALES FORECAST 2026

11.1 Vitrakvi Sales Forecast
11.2 Rozlytrek Sales Forecast

12. KEY TRK INHIBITORS DRUGS IN CLINICAL DEVELOPMENT

12.1 Selitrectinib
12.2 Repotrectinib
12.3 Taletrectinib
12.4 VMD928
12.5 ICP723
12.6 CHC2014

13. GLOBAL TRK INHIBITORS CLINICAL PIPELINE (BY DRUGS) INSIGHT

13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-III

14. MARKETED TRK INHIBITORS CLINICAL INSIGHT

15. GLOBAL TRK INHIBITORS CLINICAL PIPELINE (BY TRIALS/STUDIES) INSIGHT

15.1 By Phase
15.2 By Status
15.3 By Region

16. GLOBAL TRK INHIBITORS MARKET FUTURE OUTLOOK

17. GLOBAL TRK INHIBITOR MARKET DYNAMICS

17.1 Market Drivers
17.2 Market Challenges

18. COMPETITIVE LANDSCAPE

18.1 AstraZeneca
18.2 Aum Biosciences
18.3 Bayer
18.4 CMG Pharmaceutical
18.5 Eli Lilly & Company
18.6 InnoCare
18.7 Loxo Oncology
18.8 Ono Pharmaceutical
18.9 Pfizer
18.10 Roche
18.11 Turning Point Therapeutics

List Of Figures

LIST OF FIGURES

Figure 1-1: Resistance Mechanism in First Generation TRK Inhibitors
Figure 1-2: Development Timeline of TRK Inhibitors
Figure 2-1: Neurotrophins & Their Receptors
Figure 2-2: Role of TRK Signaling in Cancer
Figure 3-1: TRK Inhibitors – Mechanism of Action
Figure 4-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 4-2: Global – TRK Inhibitors Market by Product (US$ Million), 2020
Figure 4-3: Global – TRK Inhibitors Market by Product (%), 2020
Figure 4-4: Global – TRK Inhibitors Market by Product (US$ Million), Q1, 2021
Figure 4-5: Global – TRK Inhibitors Market by Product (US$ Million), Q2, 2021
Figure 4-6: Global – TRK Inhibitors Market by Product (US$ Million), H1, 2021
Figure 4-7: Global – TRK Inhibitors Market by Product (%), H1, 2021
Figure 4-8: Global – TRK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 4-9: TRK Inhibitor - Market by Region (US$ Million), 2020
Figure 4-10: TRK Inhibitors Market by Region (%), 2020
Figure 5-1: US – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 5-2: TRK Inhibitor Market – US vs. ROW (US$ Million), 2020
Figure 5-3: TRK Inhibitor Market – US vs. ROW (%), 2020
Figure 5-4: US - TRK Inhibitors Market by Product (US$ Million), 2020
Figure 5-5: US - TRK Inhibitors Market by Product (%), 2020
Figure 5-6: US - TRK Inhibitors Market by Product (US$ Million), H1, 2021
Figure 5-7: US - TRK Inhibitors Market by Product (%), H1, 2021
Figure 5-8: US – TRK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 5-9: Europe – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 5-10: Europe – Cancer Incidences by Country (Million), 2020
Figure 5-11: TRK Inhibitor Market – Europe vs. ROW (US$ Million), 2020
Figure 5-12: TRK Inhibitor Market – Europe vs. ROW (%), 2020
Figure 5-13: Europe - TRK Inhibitors Market by Product (US$ Million), 2020
Figure 5-14: Europe - TRK Inhibitors Market by Product (%), 2020
Figure 5-15: Europe - TRK Inhibitors Market by Product (US$ Million), H1, 2021
Figure 5-16: Europe - TRK Inhibitors Market by Product (%), H1, 2021
Figure 5-17: Europe – TRK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 5-18: Japan – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 5-19: TRK Inhibitors Market – Japan vs. ROW (US$ Million), 2020
Figure 5-20: TRK Inhibitors Market – Japan vs. ROW (%), 2020
Figure 5-21: Japan - TRK Inhibitors Market by Product (US$ Million), 2020
Figure 5-22: Japan - TRK Inhibitors Market by Product (%), 2020
Figure 5-23: Japan - TRK Inhibitors Market by Product (US$ Million), H1, 2021
Figure 5-24: Japan - TRK Inhibitors Market by Product (%), H1, 2021
Figure 5-25: Japan – TRK Inhibitor Market Size (US$ Million), 2020 - 2026
Figure 5-26: China – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 5-27: South Korea – Cancer Incidences & Deaths, 2020 & 2025
Figure 5-28: TRK Inhibitors Market – China vs. ROW (%), 2020
Figure 5-29: ROW - TRK Inhibitors Market by Product (US$ Million), H1, 2021
Figure 5-30: ROW - TRK Inhibitors Market by Product (%), H1, 2021
Figure 5-31: ROW – TRK Inhibitors Market Size (US$ Million), 2020 - 2026
Figure 6-1: Global – Lung Cancer Incidences, 2020 - 2026
Figure 6-2: Global – Non-Small Cell Lung Cancer Incidences, 2020 - 2026
Figure 6-3: Global – NTRK Positive Lung Cancer Incidences, 2020 - 2026
Figure 6-4: Global – NTRK Positive Non-Small Cell Lung Cancer Incidences, 2020 - 2026
Figure 6-5: Global – Breast Cancer Incidences, 2020 - 2026
Figure 6-6: Global – NTRK Positive Breast Cancer Incidences, 2020 - 2026
Figure 6-7: Global – Colorectal Cancer Incidences, 2020 - 2026
Figure 6-8: Global – NTRK Positive Colorectal Cancer Incidences, 2020 - 2026
Figure 6-9: Global – Thyroid Cancer Incidences, 2020 - 2026
Figure 6-10: Global – Papillary Thyroid Cancer Incidences, 2020 - 2026
Figure 6-11: Global – NTRK Positive Papillary Thyroid Cancer Incidences, 2020 - 2026
Figure 6-12: Global – Brain Cancer Incidences, 2020 - 2026
Figure 6-13: Global – Gliomlastoma Incidences, 2020 - 2026
Figure 6-14: Global – NTRK Positive Gliolastoma Incidences, 2020 - 2026
Figure 7-1: US – Vitrakvi Orphan Status & FDA Approval Year
Figure 7-2: Vitrakvi – Approval Year by Region
Figure 7-3: US – Vitrakvi Patent Approval & Expiration Year
Figure 7-4: US – Vitrakvi Patents by Assignees
Figure 8-1: US – Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 25mg Capsules (US$), October’2021
Figure 8-2: US – Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 100mg Capsules (US$), October’2021
Figure 8-3: US – Cost of Supply of 100ml & Per Unit Cost of Virtakvi 20mg/ml Oral Solution (US$), October’2021
Figure 8-4: UK – Cost of Supply of 56 Capsules & Per Unit Cost of Virtakvi 25mg Capsules (Euro/US$), October’2021
Figure 8-5: UK – Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 100mg Capsules (Euro/US$), October’2021
Figure 8-6: UK – Cost of Supply of 100ml & Per Unit Cost of Virtakvi 20mg/ml Oral Solution (Euro/US$), October’2021
Figure 8-7: Virtakvi – Recommended Initial & Dose Reductions in Adult/Pediatric Patients with at Least 1.0 Meter-Squared (mg)
Figure 8-8: Virtakvi – Recommended Initial & Dose Reductions in Pediatric Patients with Less than 1.0 Meter-Squared (mg/m2)
Figure 9-1: US – Rozlytrek Orphan Drug Designations Approval by Indication
Figure 9-2: Japan – Rozlytrek Approval Year by Indication
Figure 9-3: Rozlytrek – Approval Year by Region
Figure 9-4: US – Rozlytrek Patent Approval & Expiration Year
Figure 10-1: US – Cost of Supply of 30 Capsules & Per Unit Cost of Rozlytrek 100mg Capsules (US$), October’2021
Figure 10-2: US – Cost of Supply of 90 Capsules & Per Unit Cost of Rozlytrek 200mg Capsules (US$), October’2021
Figure 10-3: UK – Cost of Supply of 30 Capsules & Per Unit Cost of Rozlytrek 100mg Capsules (Euro/US$), October’2021
Figure 10-4: UK – Cost of Supply of 90 Capsules & Per Unit Cost of Rozlytrek 200mg Capsules (Euro/US$), October’2021
Figure 10-5: Rozlytrek – Recommended Initial & Dose Reductions in Adult/Pediatric Patients with BSA Greater than 1.50 m2 (mg/day)
Figure 10-6: Rozlytrek – Recommended Initial & Dose Reductions in Pediatric Patients with BSA of 1.11 to 1.50 m2 (mg/day)
Figure 10-7: Rozlytrek – Recommended Initial & Dose Reductions in Pediatric Patients with BSA of 0.91 to 1.1 m2 (mg/day)
Figure 10-8: Global - Rozlytrek Annual Sales (CHF/US$ Million), 2019 & 2020
Figure 10-9: US - Rozlytrek Annual Sales (CHF/US$ Million), 2019 & 2020
Figure 10-10: Rozlytrek - Annual Sales by Region (CHF/US$ Million), 2020
Figure 10-11: Rozlytrek - Annual Sales by Region (%), 2020
Figure 10-12: Global - Rozlytrek Quarterly Sales (CHF/US$ Million), 2020
Figure 10-13: Global - Rozlytrek Quarterly Sales (CHF/US$ Million), Q1 & Q2’2021
Figure 10-14: Rozlytrek –Sales by Region (CHF/US$ Million), Q1’2021
Figure 10-15: Rozlytrek – Sales by Region (CHF/US$ Million), Q2’2021
Figure 10-16: Rozlytrek – Half Year Sales by Region (CHF/US$ Million), H1’2021
Figure 10-17: Rozlytrek – Half Year Sales by Region (%), H1’2021
Figure 11-1: Global – Vitrakvi Sales Forecast (US$ Million), 2021 - 2026
Figure 11-2: Global – Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
Figure 11-3: US – Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
Figure 11-4: Europe – Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
Figure 11-5: Japan – Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
Figure 11-6: ROW – Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
Figure 12-1: Selitrectinib – Phase-I/II Clinical Study Initiation & Primary Completion Year
Figure 12-2: Taletrectinib – Phase-II Clinical Study Initiation & Primary Completion Year
Figure 12-3: VMD928 – Phase-I Clinical Study Initiation & Primary Completion Year
Figure 12-4: ICP723 – Phase-I/II Clinical Study Initiation & Primary Completion Year
Figure 13-1: Global TRK Inhibitors Clinical Pipeline insight (Number of drugs), 2021 till 2026
Figure 15-1: Global – TRK Inhibitor Clinical Trials Insight by Phase (Number of Trials), October’2021
Figure 15-2: Global - TRK Inhibitor Clinical Trials Insight by Phase (%),October’2021
Figure 15-3: Global - TRK Inhibitor Clinical Trials Insight by Status (Number of Trials), October’2021
Figure 15-4: Global - TRK Inhibitor Clinical Trials Insight by Status (%),October’2021
Figure 15-5: TRK Inhibitor – Clinical Trials Insight by Region (Number of Trials), October’2021
Figure 15-6: North America – Clinical Trial by Countries, October’2021
Figure 15-7: TRK Inhibitor – Clinical Trials Insight by Region, October’2021
Figure 15-8: North America – Clinical Trial by Countries (%),October’2021
Figure 17-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2040
Figure 17-2: Global – TRK Inhibition Market Drivers
Figure 17-3: Global – TRK Inhibitor Market Challenges